denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), epidemiology, Clinical Research, health outcomes research, Adverse Events, survivorship
Description:
Survivors of pediatric hematologic malignancies are at increased risk of long-term medical and psychosocial late effects as a consequence of their treatment, and in some instances, also secondary to underlying genetic predisposition. This educational session will review the evidence for three particularly significant toxicity categories: cardiovascular, neurocognitive, and secondary malignant neoplasms. The session will also review current screening and intervention strategies that may mitigate the development of these late effects. Finally, presenters will also highlight gaps and areas of future research.
Dr. Eric Chow will provide background on the epidemiology of long-term treatment associated cardiovascular toxicity. He will then review current prevention and screening strategies, and touch on key management considerations.
Dr. Kevin Krull will outline the risk factors that are associated with neurocognitive deficits after therapy. In this session Dr. Krull also will review potential screening options, along with primary and secondary prevention options under current study.
Dr. Smita Bhatia will review the growing data informing genetic risk factors for secondary malignant neoplasms following cancer therapies, and the potential pathophysiologic pathways they reveal. Finally, she will discuss how these data can be incorporated into future screening and prediction algorithms.
Dr. Eric Chow will provide background on the epidemiology of long-term treatment associated cardiovascular toxicity. He will then review current prevention and screening strategies, and touch on key management considerations.
Dr. Kevin Krull will outline the risk factors that are associated with neurocognitive deficits after therapy. In this session Dr. Krull also will review potential screening options, along with primary and secondary prevention options under current study.
Dr. Smita Bhatia will review the growing data informing genetic risk factors for secondary malignant neoplasms following cancer therapies, and the potential pathophysiologic pathways they reveal. Finally, she will discuss how these data can be incorporated into future screening and prediction algorithms.